Following the Friday vote in the House of Representatives which effectively blocked movement (for now) on the Trade Promotion Authority, and more generally, slowed down the TransPacific Partnership (TPP) negotiations, I was contacted by Dr. Harvey Bale, the well known former Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). In an exchange on Facebook, Dr. Bale took favorable note of the outcome on fast track, and described the vote against fast track as "A very good day, Indeed." I asked Dr.
WTO TRIPS Council (June 2015): India underscores the importance of de-linkage in discussions of financing innovationSubmitted by thiru on 10. June 2015 - 15:42
In discussions at the June 2015 WTO TRIPS Council on the role of intellectual property in financing innovation, India underscored its commitment to the principle of de-linkage by stating,
Innovation should not be viewed within the narrow prism of intellectual property monopolies but framed within a holistic, knowledge ecosystem that includes open innovation, open knowledge approaches and de-linkage of R&D costs from product prices
On Tuesday, 9 June 2015, India delivered the following statement on Non-Violation and Situational Complaints (IP/C/W/385/Rev 1). Brazil introduced the paper along with 16 other WTO members including India. The 17 co-sponsors of this paper include Argentina, Plurinational State of Bolivia, Brazil, China, Colombia, Cuba, Ecuador, Egypt, India, Indonesia, Kenya, Malaysia, Pakistan, Peru, Russian Federation, Sri Lanka and Bolivarian Republic of Venezuela.
The joint submission proposes the following action item for the Nairobi Ministerial from 15 December 2015 to 18 December 2015:
Attached below is a May 20, 2015 letter from Duke researchers to the White House Office of Science and Technology Policy, setting our problems in the TPP IP Chapter. The letter is signed by Jason Cross, the Director of the Innovation & Technology Policy Lab (ITPLab) at the Sanford School of Public Policy & Duke Law School, at Duke University.
The whole letter (available in PDF format here) is worth reading. Here are a few sections from the letter:
Attached is a 2 page summary of the main provisions in the Trans-Pacific Partnership Agreement (TPP) that will lead to higher prices for drugs and other medical technologies.
A pdf version of the note is available here: http://keionline.org/sites/default/files/KEI-TPP-Briefing-2015-2-A2M.pdf
What does the TPP do as regards prices of drugs and other medical technologies?
KEI TPP Briefing note 2015:2
June 10, 2015
WTO TRIPS Council (June 2015): LDC Group Presentation on the Extension of the Decision for Pharmaceutical ProductsSubmitted by thiru on 10. June 2015 - 8:54
The LDC Group delivered the following statement on Wednesday, 8 June 2015 during WTO TRIPS Council discussions on their request on the extension of the decision on pharmaceutical products.
PRESENTATION BY THE LDCS GROUP TO THE TRIPS COUNCIL ON THE EXTENSION OF THE DECISION ON PHARMACEUTICAL PRODUCTS, 09-10 JUNE 2015
I make this presentation on behalf of the LDCs group. We thank you for calling this meeting and for your report.
WTO TRIPS Council: World Health Organization issues unequivocal support of LDC transition period for pharmaceutical productsSubmitted by thiru on 10. June 2015 - 5:15
Today, on Wednesday, 10 June 2015, the World Trade Organization's TRIPS Council discussed the LDC Group's Request for an Extension of the Transitional Period Under Article 66.1 of the TRIPS Agreement for Least Developed Country Members with Respect to Pharmaceutical Products and for Waivers from the Obligation of Articles 70.8 and 70.9 of the TRIPS Agreement (Source: IP/C/W/605).
KEI is circulating a sign on letter to be sent to Ambassador Michael Froman of USTR. We learned that in a USTR has been stating that there was no evidence that stronger intellectual property rules created barriers for access to medicine.
This is a shocking statement for USTR to make, and we are seeking confirmation and clarification of USTR's assertion. The text of our letter follows below.
If you would like to sign on to this letter, please send your name, city and state of residence, and affiliation if any, along with contact details (only for confirmation if necessary), to:
I have written an article for Medium, titled: TPP, designed to make medicine more expensive, reforms more difficult. (Link here)
Last week, KEI published the October 3, 2014 Korea proposals for the RCEP IP Chapter (http://www.keionline.org/node/2239), and earlier we published a Japan proposal for the RCEP IP Chapter (http://keionline.org/node/2173)
Today we are publishing two new proposals for the RCEP IP Chapter, the proposals by
- India, and
US Copyright office proposes limits on damages, injunctions, for Orphan Works, contradicting TPP languageSubmitted by James Love on 4. June 2015 - 15:51
The US Copyright Office has proposed limitations on damages and injunctions, when "orphan" copyrighted works are infringed.
Attached (here) is the October 3, 2014 version of the Draft Text, of the Intellectual Property Chapter, for the Regional Comprehensive Economic Partnership (RCEP), Free Trade Agreement, tabled by South Korea in the negotiations. (More about the RCEP here)
The next round of negotiation will be held in Kyoto, Japan from 8-12 June.
WTO TRIPS Council (February 2015): EU statement on LDC extension of transition period for pharmaceutical productsSubmitted by thiru on 3. June 2015 - 4:25
The following statement was delivered by the European Union at the February 2015 session in response to the proposal by the LDC Group Request for an Extension of the Transitional Period Under Article 66.1 of the TRIPS Agreement for Least Developed Country Members with Respect to Pharmaceutical Products and for Waivers from the Obligation of Articles 70.8 and 70.9 of the TRIPS Agreement.
In particular, the European Union noted,
June 2015: WTO reports on India's Section 3(d) and compulsory licensing provisions - WTO Trade Policy Review - IndiaSubmitted by thiru on 2. June 2015 - 7:29
On 2 June 2015 and 4 June 2015, the World Trade Organization (WTO) is conducting a trade policy review of India. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place in the "Trade Policy Review Body which is actually the WTO General Council — comprising the WTO’s full membership — operating under special rules and procedures" (Source: WTO, Trade Policy Reviews: Brief Introduction).
For any of you in Bucharest this weekend at the EASL conference on liver disease, KEI Europe will host a side event on access to affordable HCV medicines on Saturday morning.
Pathways to Widespread Access: Affordable HCV Medicines in Romania
Date: 10:00-12:00 Saturday, 30 May 2015
Venue: Novotel Bucharest City Centre, Conference Room Lyon (Mezzanine Floor)
A Panel Discussion:
Peter Beyer, World Health Organization (WHO). Access to Medicines and Intellectual Property Rights